- Home
- ELVN vs TPB Comparison
ELVN vs TPB Comparison
Compare ELVN & TPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- TPB
- Stock Information
- Founded
- ELVN 2016
- TPB 1988
- Country
- ELVN United States
- TPB United States
- Employees
- ELVN N/A
- TPB N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- TPB Tobacco
- Sector
- ELVN Health Care
- TPB Consumer Discretionary
- Exchange
- ELVN Nasdaq
- TPB Nasdaq
- Market Cap
- ELVN 1.1B
- TPB 1.1B
- IPO Year
- ELVN 2020
- TPB 2016
- Fundamental
- Price
- ELVN $21.86
- TPB $57.51
- Analyst Decision
- ELVN Strong Buy
- TPB Strong Buy
- Analyst Count
- ELVN 5
- TPB 4
- Target Price
- ELVN $37.80
- TPB $68.75
- AVG Volume (30 Days)
- ELVN 241.0K
- TPB 175.4K
- Earning Date
- ELVN 03-13-2025
- TPB 02-26-2025
- Dividend Yield
- ELVN N/A
- TPB 0.49%
- EPS Growth
- ELVN N/A
- TPB 283.79
- EPS
- ELVN N/A
- TPB 2.48
- Revenue
- ELVN N/A
- TPB $409,407,000.00
- Revenue This Year
- ELVN N/A
- TPB $3.01
- Revenue Next Year
- ELVN N/A
- TPB $2.26
- P/E Ratio
- ELVN N/A
- TPB $23.20
- Revenue Growth
- ELVN N/A
- TPB 0.28
- 52 Week Low
- ELVN $10.90
- TPB $21.98
- 52 Week High
- ELVN $30.03
- TPB $66.18
- Technical
- Relative Strength Index (RSI)
- ELVN 44.27
- TPB 48.58
- Support Level
- ELVN $21.45
- TPB $55.72
- Resistance Level
- ELVN $22.82
- TPB $59.17
- Average True Range (ATR)
- ELVN 1.55
- TPB 1.84
- MACD
- ELVN 0.00
- TPB -0.02
- Stochastic Oscillator
- ELVN 32.63
- TPB 45.70
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About TPB Turning Point Brands Inc.
Turning Point Brands Inc operates as manufacturer, marketer, provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in three segments namely Zig-Zag products; Stoker's products and NewGen products. The company generates maximum revenue from the Zig-Zag products segment.